2nd Annual Best Practice in Clinical Site Selection & Management

2-4 March, 2009, Cascais (Lisbon), Portugal.
This event will present a fresh and original perspective on improving the performance of clinical trials. It will be looking at improving efficiency when selecting clinical sites and managing an individual site's performance.

This event will be unique because other events are all looking at the same broad, big picture, overall, general, top-down, approach to improving clinical performance. The difference with this event is that the conference will be looking specifically at best practice at the individual site level and what can be done to maximize quality, increase patient recruitment and retention and save time at each single site. Assuming performance can be maximised at each individual site, then the overall global clinical trial will be naturally faster and more productive across all sites.

Find your reasons to attend

  • Meet experts dealing with challenges faced directly at the site on a daily basis.
  • Understand the perspectives of all stakeholders involved, i.e. sponsors, CROs, SMOs and the actual clinical sites.
  • Come to benchmark, share experience and help to develop a best-practice approach to site selection and patient recruitment performance.
  • Build stronger relationships upon a better understanding of the challenges faced by each group, who are all vital to the success of a study.
  • Participate in post-conference interactive workshop focused on maximising site performance by improving relationships between sponsor/CRO and site clinical teams.

Who will benefit:

  • PHARMA:
    VPs, directors, and managers of:
    Clinical Research, Clinical Operations, Patient Recruitment, Clinical Quality Assurance, Medical Affairs, Regulatory Affairs, Medical Directors Clinical Project Managers, Clinical Study Managers, CRAs
  • CROs and SMOs:
    Business Development, Clinical Operations
  • CLINICAL SITE:
    Professors, Investigators, Study nurses

For further information and registration, please visit:
http://www.nextlevelpharma.com/events/view/20

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...